Discovery research: the scientific challenge of finding new antibiotics

Research output: Contribution to journalArticlepeer-review

Standard

Discovery research : the scientific challenge of finding new antibiotics. / Livermore, David M; British Society for Antimicrobial Chemotherapy Working Party on The Urgent Need: Regenerating Antibacterial Drug Discovery and Development ; Piddock, Laura.

In: Journal of Antimicrobial Chemotherapy, Vol. 66, No. 9, 09.2011, p. 1941-4.

Research output: Contribution to journalArticlepeer-review

Harvard

Livermore, DM, British Society for Antimicrobial Chemotherapy Working Party on The Urgent Need: Regenerating Antibacterial Drug Discovery and Development & Piddock, L 2011, 'Discovery research: the scientific challenge of finding new antibiotics', Journal of Antimicrobial Chemotherapy, vol. 66, no. 9, pp. 1941-4. https://doi.org/10.1093/jac/dkr262

APA

Livermore, D. M., British Society for Antimicrobial Chemotherapy Working Party on The Urgent Need: Regenerating Antibacterial Drug Discovery and Development, & Piddock, L. (2011). Discovery research: the scientific challenge of finding new antibiotics. Journal of Antimicrobial Chemotherapy, 66(9), 1941-4. https://doi.org/10.1093/jac/dkr262

Vancouver

Livermore DM, British Society for Antimicrobial Chemotherapy Working Party on The Urgent Need: Regenerating Antibacterial Drug Discovery and Development, Piddock L. Discovery research: the scientific challenge of finding new antibiotics. Journal of Antimicrobial Chemotherapy. 2011 Sep;66(9):1941-4. https://doi.org/10.1093/jac/dkr262

Author

Livermore, David M ; British Society for Antimicrobial Chemotherapy Working Party on The Urgent Need: Regenerating Antibacterial Drug Discovery and Development ; Piddock, Laura. / Discovery research : the scientific challenge of finding new antibiotics. In: Journal of Antimicrobial Chemotherapy. 2011 ; Vol. 66, No. 9. pp. 1941-4.

Bibtex

@article{9c075caabbf4413e8b0cd9821619b06a,
title = "Discovery research: the scientific challenge of finding new antibiotics",
abstract = "The dwindling supply of new antibiotics largely reflects regulatory and commercial challenges, but also a failure of discovery. In the 1990s the pharmaceutical industry abandoned its classical ways of seeking antibiotics and instead adopted a strategy that combined genomics with high-throughput screening of existing compound libraries. Too much emphasis was placed on identifying targets and molecules that bound to them, and too little emphasis was placed on the ability of these molecules to permeate bacteria, evade efflux and avoid mutational resistance; moreover, the compound libraries were systematically biased against antibiotics. The sorry result is that no antibiotic found by this strategy has yet entered clinical use and many major pharmaceutical companies have abandoned antibiotic discovery. Although a raft of start-up companies-variously financed by venture capital, charity or public money--are now finding new antibiotic compounds (some of them very promising in vitro or in early trials), their development through Phase III depends on financial commitments from large pharmaceutical companies, where the discouraging regulatory environment and the poor likely return on investment remain paramount issues.",
keywords = "Anti-Bacterial Agents, Bacterial Infections, Capital Expenditures, Drug Discovery, Drug Industry, Drug Resistance, Bacterial, Genomics, Humans",
author = "Livermore, {David M} and {British Society for Antimicrobial Chemotherapy Working Party on The Urgent Need: Regenerating Antibacterial Drug Discovery and Development} and Laura Piddock",
year = "2011",
month = sep,
doi = "10.1093/jac/dkr262",
language = "English",
volume = "66",
pages = "1941--4",
journal = "Journal of Antimicrobial Chemotherapy",
issn = "0305-7453",
publisher = "Oxford University Press",
number = "9",

}

RIS

TY - JOUR

T1 - Discovery research

T2 - the scientific challenge of finding new antibiotics

AU - Livermore, David M

AU - British Society for Antimicrobial Chemotherapy Working Party on The Urgent Need: Regenerating Antibacterial Drug Discovery and Development

AU - Piddock, Laura

PY - 2011/9

Y1 - 2011/9

N2 - The dwindling supply of new antibiotics largely reflects regulatory and commercial challenges, but also a failure of discovery. In the 1990s the pharmaceutical industry abandoned its classical ways of seeking antibiotics and instead adopted a strategy that combined genomics with high-throughput screening of existing compound libraries. Too much emphasis was placed on identifying targets and molecules that bound to them, and too little emphasis was placed on the ability of these molecules to permeate bacteria, evade efflux and avoid mutational resistance; moreover, the compound libraries were systematically biased against antibiotics. The sorry result is that no antibiotic found by this strategy has yet entered clinical use and many major pharmaceutical companies have abandoned antibiotic discovery. Although a raft of start-up companies-variously financed by venture capital, charity or public money--are now finding new antibiotic compounds (some of them very promising in vitro or in early trials), their development through Phase III depends on financial commitments from large pharmaceutical companies, where the discouraging regulatory environment and the poor likely return on investment remain paramount issues.

AB - The dwindling supply of new antibiotics largely reflects regulatory and commercial challenges, but also a failure of discovery. In the 1990s the pharmaceutical industry abandoned its classical ways of seeking antibiotics and instead adopted a strategy that combined genomics with high-throughput screening of existing compound libraries. Too much emphasis was placed on identifying targets and molecules that bound to them, and too little emphasis was placed on the ability of these molecules to permeate bacteria, evade efflux and avoid mutational resistance; moreover, the compound libraries were systematically biased against antibiotics. The sorry result is that no antibiotic found by this strategy has yet entered clinical use and many major pharmaceutical companies have abandoned antibiotic discovery. Although a raft of start-up companies-variously financed by venture capital, charity or public money--are now finding new antibiotic compounds (some of them very promising in vitro or in early trials), their development through Phase III depends on financial commitments from large pharmaceutical companies, where the discouraging regulatory environment and the poor likely return on investment remain paramount issues.

KW - Anti-Bacterial Agents

KW - Bacterial Infections

KW - Capital Expenditures

KW - Drug Discovery

KW - Drug Industry

KW - Drug Resistance, Bacterial

KW - Genomics

KW - Humans

U2 - 10.1093/jac/dkr262

DO - 10.1093/jac/dkr262

M3 - Article

C2 - 21700626

VL - 66

SP - 1941

EP - 1944

JO - Journal of Antimicrobial Chemotherapy

JF - Journal of Antimicrobial Chemotherapy

SN - 0305-7453

IS - 9

ER -